Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinjun Hou

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Plos Neglected Tropical Diseases|May 4, 2026
Establishment and characterization of a Wolbachia (wAlbB)-infected Aedes aegypti line (Tw-Kao) for dengue controlHui-Ying Yu, Bo-Yu Chen, Ying-Tsong Chen, et al.
Journal of Medicinal Chemistry|December 21, 2016
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide FunctionalityChristopher R Butler, Kevin Ogilvie, Luis Martinez-Alsina, et al.
Nature Communications|October 12, 2016
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitorsAndrea M Zuhl, Charles E Nolan, Michael A Brodney, et al.
Journal of Chemical Theory and Computation|December 29, 2023
Development and Comprehensive Benchmark of a High-Quality AMBER-Consistent Small Molecule Force Field with Broad Chemical Space Coverage for Molecular Modeling and Free Energy CalculationBai Xue, Qingyi Yang, Qiaochu Zhang, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Journal of Medicinal Chemistry|April 4, 2020
Current and Future Roles of Artificial Intelligence in Medicinal Chemistry SynthesisThomas J Struble, Juan C Alvarez, Scott P Brown, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Plos Neglected Tropical Diseases|May 4, 2026
Establishment and characterization of a Wolbachia (wAlbB)-infected Aedes aegypti line (Tw-Kao) for dengue controlHui-Ying Yu, Bo-Yu Chen, Ying-Tsong Chen, et al.
Journal of Medicinal Chemistry|December 21, 2016
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide FunctionalityChristopher R Butler, Kevin Ogilvie, Luis Martinez-Alsina, et al.
Nature Communications|October 12, 2016
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitorsAndrea M Zuhl, Charles E Nolan, Michael A Brodney, et al.
Journal of Chemical Theory and Computation|December 29, 2023
Development and Comprehensive Benchmark of a High-Quality AMBER-Consistent Small Molecule Force Field with Broad Chemical Space Coverage for Molecular Modeling and Free Energy CalculationBai Xue, Qingyi Yang, Qiaochu Zhang, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Journal of Medicinal Chemistry|April 4, 2020
Current and Future Roles of Artificial Intelligence in Medicinal Chemistry SynthesisThomas J Struble, Juan C Alvarez, Scott P Brown, et al.
Pageof 5